Login  /  Register  | 3 premium articles left before you must register.


Published 02/23/2013 12:00 AM
Updated 02/22/2013 11:55 PM

A Pfizer Inc. drug discovered by Pfizer Inc. scientists in California and developed largely in Groton has received the cold shoulder from healthcare pricing authorities in Germany.

Pfizer's cancer drug Xalkori received an initial turndown from the Institute for Quality and Efficiency in Health Care, which weighs the costs of new drugs when deciding on which medicines the German government will fund.

According to the industry blog FiercePharma, Xalkori received a "no additional benefit" tag from the agency, meaning it wasn't better than established drugs.

Pfizer argues that Xalkori provides significant benefit for a limited subset of lung cancer patients.

Town News

Visit Zip06
Submit Your:  Submit Your News Submit Your Photos Submit Your Events
Most Recent Poll
It's Oscar Sunday. What are you most interested in watching?
I want to see if Ben Affleck hands it to the Oscar voters by winning Best Picture with Argo.
I want to see the Chastain vs. Lawrence faceoff in the Best Actress category.
I won't be tuning in. Meryl Streep isn't up for anything and I'm peeved our local Hope Springs wasn't recognized.
I'm still fuming about Kushner's Lincoln inaccuracies.
I'll be watching The Walking Dead instead.
Number of votes: 437

No current items found